In non-small cell lung cancer Apatinib reverses the drug resistance to gefitinib because of different mechanisms: synergistic effect on VEGFR2 and EGFR signaling pathways; or due to Warburg effect when a high rate of glycolysis exhausts the tumor growth32. The gene discussed is KDR; the disease is non-small cell lung carcinoma.